Pulpitis - Irreversible, Anesthesia, Local
Conditions
Keywords
Pulpitis, irreversible Pulpitis, Hot tooth, Cataflam, Diclofenac Potassium, Preoperative, Premedication, Analgesic, Local anesthesia, Articaine, Buccal infiltration
Brief summary
The purpose of this study is to assess the effect of preoperative Diclofenac Potassium (50 mg Cataflam) on the anesthetic success of buccal infiltration with 4% articaine with epinephrine 1:200,000 in mandibular molars with symptomatic irreversible pulpitis.
Detailed description
This study aims to evaluate the effectiveness of preoperative administration of Diclofenac Potassium (50 mg Cataflam) compared to placebo, one hour before treatment, on the anesthetic success of buccal infiltration with 4% articaine with epinephrine 1:200,000 in mandibular molars with symptomatic irreversible pulpitis. Patients with moderate-to-severe pre-operative pain are selected. Full medical and dental history will be obtained from all patients treated during this study by the operator. Clinical diagnosis of symptomatic irreversible pulpitis is to be confirmed. The primary outcome is success of buccal infiltration using articaine.The secondary outcomes are pain on injection. Patients will be recruited from the outpatient clinic of Endodontics at the Faculty of Oral and Dental Medicine, Cairo University.
Interventions
A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
DRUGPlacebo
A placebo will be taken one hour before initiation of endodontic treatment.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
The patients will be randomly divided into 2 groups: Experimental group: Diclofenac Potassium (50 mg, Cataflam) to be administered one hour before treatment. Control group: Placebo to be administered one hour before treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients with active pain (moderate-to-severe) in mandibular molars. * Patients with prolonged response to cold testing and electric pulp tester. * Patient with the ability to understand and use pain scales. * Patient with vital coronal pulp tissue on access. * Patient who accept to enroll to the study.
Exclusion criteria
* Patients' allergies or any other contraindication to diclofenac potassium or articaine. * Pregnant and lactating females. * Patients having pain medication in the last 6 hours. * Patient has more than one symptomatic mandibular tooth in the same quadrant. * Patients with periradicular pathosis and/or radiolucency other than widened periodontal ligaments. * Patients with active peptic ulcer and gastrointestinal disorders. * Patients with history of bleeding problems or anticoagulant use within the last month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Success of articaine buccal infiltration. | Intraoperative | Success of buccal infiltration using articaine. It will be measured using Heft-Parker visual analogue scale. The success will be considered if patient experienced no or mild pain (Heft-Parker VAS rating less than 54mm) while the failure will be considered if patient experience moderate-or-severe pain (Heft-parker VAS rating greater than 54mm) during access into dentin, access into pulp chamber or instrumentation of the canals. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain on injection | Intraoperative | The secondary outcome is pain on injection. It will be measured by Heft-Parker visual analogue scale during local anesthesia administration. |
Countries
Egypt
Outcome results
None listed